Sermorelin 10mg Research Peptide

Sermorelin 10mg is a synthetic 29–amino acid research peptide classified as growth hormone–releasing hormone (GHRH 1–29) amide, the shortest biologically active fragment of native GHRH. Supplied as a lyophilized powder with a reported purity greater than 99%, Sermorelin 10mg is studied in laboratory and preclinical settings for its interaction with pituitary signaling pathways related to endogenous growth hormone secretion. This compound is intended strictly for laboratory research use.

What Is Sermorelin 10mg?

Sermorelin 10mg is a truncated analog of human GHRH, designed to retain receptor activity while offering improved stability compared to the full 44–amino acid peptide. First explored in research during the early 1980s, Sermorelin has been used extensively in experimental models examining growth hormone secretagogue mechanisms and endocrine signaling dynamics.

Sermorelin 10mg is an experimental research compound and is not approved for human or animal use.

Research Background

Native growth hormone–releasing hormone stimulates the anterior pituitary gland to release pulsatile growth hormone, which subsequently influences downstream pathways including insulin-like growth factor 1 (IGF-1) production. By isolating the first 29 amino acids of GHRH, researchers created Sermorelin to maintain receptor binding while simplifying molecular structure.

Animal and in vitro studies have shown that Sermorelin can activate pituitary somatotroph cells, leading to increased growth hormone release and secondary IGF-1 signaling. These findings remain preclinical and have not been validated in human clinical trials.

Mechanisms of Research Interest

GHRH Receptor Activation

Sermorelin 10mg has been studied for its ability to bind to GHRH receptors on pituitary somatotroph cells, initiating intracellular signaling pathways associated with growth hormone secretion.

Pulsatile Growth Hormone Release

Unlike direct administration of growth hormone in experimental models, Sermorelin has been examined for its ability to support endogenous, rhythmic growth hormone release, preserving natural endocrine signaling patterns.

IGF-1 Signaling Research

Growth hormone release stimulated by Sermorelin has been studied for its downstream effect on IGF-1 production, a key mediator involved in anabolic and growth-related signaling pathways.

Endocrine Selectivity

Research observations suggest Sermorelin does not significantly alter other hormonal systems, including prolactin, insulin, cortisol, glucose, or thyroid hormone levels, making it a compound of interest in selective endocrine signaling studies.

All mechanisms described are experimental observations only and do not imply therapeutic benefit.

Molecular and Chemical Information

• Product Name: Sermorelin 10mg

• Form: Lyophilized powder

• Purity: Greater than 99%

• Peptide Length: 29 amino acids

• Classification: GHRH (1–29) amide

• Estimated Half-Life: Approximately 11–12 minutes

• Alternate Names: GHRH (1–29) amide, GHRF (1–29)

Research Applications

Sermorelin 10mg may be utilized by qualified researchers in laboratory investigations involving:

• Growth hormone–releasing hormone receptor signaling

• Endocrine pathway and pituitary function research

• IGF-1 and anabolic signaling studies

• Pulsatile hormone secretion modeling

All use must remain within controlled laboratory environments.

Regulatory Status and Use Disclaimer

• For research use only

• Not approved by the Food and Drug Administration

• Not intended for human or veterinary use

• Not intended to diagnose, treat, cure, or prevent any disease

• No established clinical safety, dosing, or efficacy data